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Cognitive function declines with age and appears to correlate with decreased cerebral metabolic rate (CMR). Caloric restriction, an
antiaging manipulation that extends life-span and can preserve cognitive function, is associated with decreased glucose uptake,
decreased lactate levels, and increased ketone body (KB) levels in the brain. Since the majority of brain nutrients come from the
periphery, this study examined whether the capacity to regulate peripheral glucose levels and KB production diﬀers in animals
with successful cognitive aging (growth hormone receptor knockouts, GHRKOs) versus unsuccessful cognitive aging (the 3xTg-
AD mouse model of Alzheimer’s disease). Animals were fasted for 5 hours with their plasma glucose and KB levels subsequently
measured. Intriguingly, in GHRKO mice, compared to those in controls, fasting plasma glucose levels were signiﬁcantly
decreased while their KB levels were signiﬁcantly increased. Conversely, 3xTg-AD mice, compared to controls, exhibited
signiﬁcantly elevated plasma glucose levels and signiﬁcantly reduced plasma KB levels. Taken together, these results suggest that
the capacity to provide the brain with KBs versus glucose throughout an animal’s life could somehow help preserve cognitive
function with age, potentially through minimizing overall brain exposure to reactive oxygen species and advanced glycation end
products and improving mitochondrial function.
1. Introduction
Aging is associated with a decline in cognitive function. Dur-
ing “normal” aging, individuals can either maintain cognitive
performance or exhibit cognitive decline accompanied by a
decrease in cerebral metabolic rate (CMR). Moreover, with
pathological aging (i.e., with Alzheimer’s disease (AD)), the
degree of cognitive decline and decrease in CMR is even
greater [1–3]. During both “normal” and pathological aging,
this decrease in CMR appears to actually precede structural
changes and the decline in cognitive function.
The antiaging manipulation known as caloric restriction
(CR) has been shown to extend life-span in a diversity of
species [4–6]. Further, it is generally believed that CR can
preserve or improve cognitive function during aging with
studies showing that (1) long-term reductions in energy
intake can enhance cognitive performance in rats and mice
[7, 8], (2) verbal memory is improved in elderly humans with
a 30% reduction in caloric intake [9], (3) age-related deﬁcits
in learning and motor coordination are reduced by CR in
rodents [10–12], and (4) AD-associated pathogenesis and
cognitive decline are minimized or improved in the 3xTg-
AD mouse model under caloric restriction [13]. However,
the eﬀect of CR is somewhat controversial since several other
studies have reported no beneﬁcial eﬀects on spatial learning
in both rats and mice [14–16], and one study using rats even
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reported a worsening of cognitive function despite increased
longevity [17]. While the existing reason for this discrepancy
in the literature is unknown, diﬀerences in the background
strain, genotype, age of the animals used in the study, the
duration of the treatment, or the speciﬁc diet used (e.g., dif-
ferential composition of medium chain fatty acids [18])
could play a role. In this regard, it is interesting to note that
recent experiments using multimetric neuroimaging have
shown that CR decreases glucose uptake and lactate levels
in the central nervous system (CNS) while KB levels are
increased [19]. Thus, the antiaging beneﬁts of CR may be
due in part to this shift in metabolic phenotype, although fur-
ther experiments are required that directly test this hypothe-
sis. This idea however does gain some support from recent
studies which demonstrate that ketone body supplementa-
tion can improve cognitive function in mild cognitive
impairment (MCI) and AD [20]). Since the majority of nutri-
ents utilized by the central nervous system (CNS) are derived
from the periphery, we tested the hypothesis that the capacity
to regulate peripheral glucose levels and produce KBs diﬀers
in animals that exhibit successful versus unsuccessful cogni-
tive aging. Speciﬁcally, is peripheral glucose regulation
enhanced in growth hormone receptor knockout (GHRKO)
mice? GHRKO mice (GHR−/−) exhibit an extended life-
span and do not show cognitive decline with age compared
to controls, as assessed with the inhibitory avoidance task
[21]. Further, is peripheral glucose regulation impaired in
the 3xTg-AD mouse model of AD (3xTg-AD)? 3xTg-AD
mice exhibit a decline in performance on numerous tasks
with age [22], and their decrease in hippocampal-
dependent cognitive function is associated with a decrease
in CMR (i.e., glucose utilization) [23]. Conversely, could
the degree of KB production be elevated in GHRKO mice
yet decreased in 3xTg-AD mice? To test this hypothesis, ani-
mals were fasted for 5 hours with their plasma glucose and
KB levels subsequently measured and comparisons made
between each mouse model and their respective controls.
2. Materials and Methods
2.1. Animals. Male GHRKO (GHR−/−) mice (4–6 months)
and wild-type or heterozygote littermate controls (GHR+/?)
as well as 3xTg-AD mice (4–6 months) and wild-type con-
trols were used for the experiments examining fasting plasma
glucose and KB levels; all animals came from local breeding
colonies at Southern Illinois University School of Medicine,
Springﬁeld and Carbondale, IL, respectively. Although male
and female mice can exhibit diﬀerences in their metabolic
proﬁles and thus diﬀerent plasma glucose and ketone body
levels [24, 25], male mice were exclusively used in this study
to minimize any potential confound associated with meta-
bolic changes seen in females during the diﬀerent stages of
the oestrus cycle [26]. The GHRKO colony was originally
established by crossing 129Ola and BALB/c N (GHR+/−)
mice with mice derived from crosses of C57BL/6 and C3H/
J strains and has been maintained on this heterogeneous
genetic background to more closely resemble a natural popu-
lation. GHRKO mice were identiﬁed versus controls due to
their reduced body size, weight, and length. 3xTg-AD mice
were created by expressing mutated human amyloid precur-
sor protein (hAPP) and human hyperphosphorylated tau
primarily in the CNS through the use of a Thy1.2 promoter.
These mice were subsequently mated to a PS1 mutant line to
create the triple mutant [27] and thus are on a mixed C57BL/
6J and C129 background. Wild-type controls were on the
same background. All animals were housed in their respec-
tive vivariums and were kept on a 12 hr/12 hr light-dark cycle
with Purina rodent chow (fat—13.5%, protein—28.5%, and
carbohydrates—58%) and water provided ad libitum. All
experiments were approved by the Institutional Animal Care
and Use Committees (IACUC) at the respective sites and
comply with the guidelines set forth by the National Insti-
tutes of Health.
2.2. Measuring and Comparing Plasma Glucose/Ketone
Levels. To examine the periphery’s capacity to regulate
plasma glucose levels and produce KBs in GHRKO and
3xTg-AD mice, versus respective controls, mice were fasted
for 5 hours with blood glucose and KB measurements subse-
quently made in duplicate using Precision Xtra glucometers
(Abbott, Abbott Park, IL) and blood glucose or blood β-
ketone strips (Abbott, Abbott Park, IL), respectively. Since
background strain can dramatically aﬀect peripheral meta-
bolic function [28–30], statistical comparisons were only
made between groups on the same background (i.e., GHR
−/− versus GHR+/?; 3xTg-AD versus 129/C57BL6 wild
types) using unpaired t-tests (Prism GraphPad 4.1, San
Diego, CA).
3. Results
As shown in Figure 1, following a ﬁve-hour fast, GHRKO
mice exhibit signiﬁcantly decreased plasma glucose levels
compared to controls (p = 0 001). Conversely, their plasma
KB levels were signiﬁcantly elevated (p < 0 02). In contrast,
3xTg-AD mice showed the exact opposite (Figure 2). Specif-
ically, plasma glucose levels were signiﬁcantly elevated in
3xTg-AD mice compared to controls (p < 0 005) while
plasma KB levels were signiﬁcantly decreased (p < 0 03).
4. Discussion
Among the most common neurological changes seen with
age is a decline in cognitive function. Hippocampal-
dependent learning and memory can be compromised with
age in humans, nonhuman primates, and rodents [31–33].
Data suggest that this aging-related decline in hippocampal
function is associated with altered bioenergetic properties.
Speciﬁcally, modern imaging techniques reveal an aging-
related decline in energy metabolism in the hippocampal
formation of individuals undergoing “normal” as well as
pathological aging [34–37], and the degree of hypometabo-
lism observed (i.e., reduced glucose utilization) correlates
with the extent of cognitive decline. While glucose is the pre-
ferred metabolic substrate of neurons and astrocytes in the
adult CNS, a variety of alternative substrates including
monocarboxylates (i.e., lactate, pyruvate, and acetate) and
KBs (i.e., β-hydrobutyrate, acetoacetate, and acetone) can
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be oxidized to generate ATP. Further, monocarboxylates
[38–41] and KBs [39, 41] can maintain synaptic eﬃcacy
and plasticity, the basis of cognitive function. In this regard,
caloric restriction (CR) has been shown to cause decreased
glucose uptake, decreased lactate levels, and elevated KB
levels in the CNS [19]. Taken together, these data suggest that
a reduction in glucose utilization and an increase in KB utili-
zation could contribute to cognitive preservation with age.
Consequently, since the CNS primarily derives it nutrients
from the periphery, this study examined whether the regula-
tion of plasma glucose and KB levels is altered early on in the
life-span of GHRKO mice which exhibit cognitive preserva-
tion and the 3xTg-AD mouse model which develops cogni-
tive impairment. The main ﬁndings of our current study
were (1) as early as 4–6 months of age, GHRKO mice,
compared to controls, exhibit signiﬁcantly decreased fast-
ing plasma glucose levels and elevated KB levels while
(2) 3xTg-AD mice exhibit signiﬁcantly elevated plasma
glucose levels and signiﬁcantly reduced KB levels com-
pared to controls.
These data suggest that the capacity of the CNS to inter-
mittently switch metabolic utilization from glucose to KBs
throughout a host’s life-span could positively impact age-
related cognitive status. Speciﬁcally, in GHRKO mice, the
reduction in plasma glucose levels coupled with elevated
KB levels following fasting suggests that the CNS in GHRKO
mice is intermittently more dependent on ketone bodies to































































Figure 2: Fasting plasma glucose and ketone levels in 3xTg-AD mice and controls. (a) 3xTg-AD mice exhibited signiﬁcantly greater plasma
glucose levels compared to controls following a 5-hour fast. (b) 3xTg-ADmice exhibited signiﬁcantly lower plasma ketone levels compared to
controls following a 5-hour fast.
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Figure 1: Fasting plasma glucose and ketone levels in GHRKO mice and controls. (a) GHRKO mice exhibited signiﬁcantly lower plasma
glucose levels compared to controls following a 5-hour fast. (b) GHRKO mice exhibited signiﬁcantly greater plasma ketone levels
compared to controls following a 5-hour fast.
3International Journal of Endocrinology
AD mice, the reduction in KB production and elevation of
plasma glucose suggest an enhanced dependence of the
3xTg-AD CNS on glucose utilization. While cognitive func-
tion was not compared in the current study, due to cognitive
preservation in GHRKO and 3xTg-ADmice at this early time
point [21, 42], it is interesting to note the variability observed
in plasma glucose and ketone body levels within an individ-
ual group. This raises the question of whether this variability
in metabolic phenotype within a group could account for the
variability observed in cognitive performance within either
GHRKO, 3xTg-AD, or control groups with age. The reason
for this diﬀerence in the capacity of the periphery to regulate
plasma glucose and KB levels in GHRKO and 3xTg-AD mice
is unknown, although one parsimonious explanation is that
the capacity of the liver to undergo gluconeogenesis and beta
oxidation diﬀers in these mouse models. Further investiga-
tion is however required to directly test this postulation.
Regardless, both a decrease in glucose dependence and an
increase in KB utilization by the CNS could potentially con-
tribute beneﬁcial eﬀects.
Cellular glucose utilization leads to the generation of
reactive oxygen species (ROS) as well as advanced glycation
end products (AGEs). During both “normal” aging and dia-
betes, the two leading risk factors for AD, AGEs are known
to accumulate in the plasma and in various tissues at an
accelerated rate [43, 44]. The main pathological consequence
of AGEs interacting with their receptor (RAGE) is the induc-
tion of intracellular reactive oxygen species (ROS) [45]. Sub-
sequently, ROS can lead to oxidative stress and sustained
inﬂammatory responses, which could ultimately translate
into irreversible cell damage, slow degeneration, and eventual
cell death or synapse loss [46]. Thus, decreasing the meta-
bolic dependency of glucose throughout a subject’s life-span
could in turn reduce the amount of oxidative damage and
lead to successful cognitive aging.
Enhanced KB utilization throughout a subject’s life-span
could also contribute to cognitive preservation. First, β-
hydroxybutyrate (BHB), the primary KB, can inhibit histone
deacetylases [47] and also increase cytoplasmic acetyl CoA
[48] which in turn subsequently increases histone acetyl-
transferase activity. Both of these changes can result in
increased gene transcription contributing to longevity [45]
and the formation of long-term implicit and explicit mem-
ory [49, 50]. Second, BHB can also decrease inﬂammation
which results in a reduction in ROS and mitochondrial oxi-
dative damage, thereby improving mitochondrial eﬃcacy
[51, 52]. Mitochondrial dysfunction has been linked to cog-
nitive decline in numerous neuropathological conditions
[53–55], and experimentally disrupting mitochondrial respi-
ratory complex activity can impair synaptic eﬃcacy and
plasticity [56].
KBs can also directly impact AD-related pathogenesis
and cognitive dysfunction. Treating animal models of AD
with ketone esters results in elevated plasma KB levels and
has been shown to slow or prevent AD pathology and
improve cognitive performance [57]. Similarly, in a multi-
center clinical trial with AC-1202 treatment, a drug that
increases plasma BHB levels, improvement in Alzheimer’s
disease assessment scale (ADAS) cognitive scores was
observed [58]. Further elevated plasma and brain ketone
body levels could also aﬀect AD via a variety of other mech-
anisms including (1) the blockade of Aβ1–42 (the toxic form
of β-amyloid) entry into neurons which can decrease oxida-
tive stress and amyloid burden [59] and (2) neuroprotection
against β-amyloid toxicity possibly by decreasing ROS pro-
duction and decreasing BACE1 expression, the rate-limiting
enzyme in Aβ1–42 production [60]. These beneﬁcial eﬀects
of BHB on AD pathogenesis and cognitive decline are
intriguing given our data demonstrating a decreased capacity
of the periphery to produce/provide KBs following a brief fast
in the 3xTg-AD mouse model. In this regard, it is interesting
to note that while CNS glucose uptake/utilization is
decreased in AD, there is no change in KB uptake/utilization
[61]. This raises the question as to whether a reduced KB
supply to the CNS throughout a subject’s life-span could
potentially contribute to AD pathogenesis. Interestingly, Klo-
sinski et al. [62] recently reported that aged female mice, a
model of postmenopausal females which exhibit the greatest
risk for sporadic AD, exhibit a precipitous drop in plasma
ketone bodies and a concomitant increase in brain ketone
body levels that appears to be the result of white matter deg-
radation (i.e., catabolism). Thus, it is possible that a
decreased capacity of the periphery to provide ketone bodies
to the brain as an alternative fuel source could trigger white
matter catabolism. The degradation of white matter, a char-
acteristic of AD that correlates with cognitive status [63],
would in turn be able to provide fatty acids for astrocytic beta
oxidation and consequently elevated brain ketone body levels
in an attempt to provide fuel at the expense of the network
connectivity. Thus, further investigation into whether plasma
KB levels may also be decreased in humans with AD or those
with an enhanced susceptibility to AD (i.e., those exhibiting
major risk factors such as diabetes) is warranted.
In conclusion, this study demonstrated an association
between altered plasma glucose and KB levels during an ani-
mal’s life-span and their capacity to eventually maintain cog-
nitive function with age. These results are also consistent
with those of studies on the beneﬁcial eﬀects of CR on
aging-related cognitive performance, since CR results in
decreased CNS glucose and lactate levels yet elevated KB
levels. Taken together, these data reveal the importance of
metabolite production and utilization during aging and illus-
trate the need for additional studies that examine why and
how these diﬀerences in metabolite regulation/production
occur in GHRKO versus 3xTg-AD mice.
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